Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma-Reference-Cited by-同舟云学术

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

Published:2014-02-24 Issue:4 Volume:124 Page:1582-1586
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Imielinski Marcin,Greulich Heidi,Kaplan Bethany,Araujo Luiz,Amann Joseph,Horn Leora,Schiller Joan,Villalona-Calero Miguel A.,Meyerson Matthew,Carbone David P.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference21 articles.

1. Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

2. New Targetable Oncogenes in Non–Small-Cell Lung Cancer

3. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

4. Genome Sequencing Identifies a Basis for Everolimus Sensitivity

5. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling from RAS to RAF: The Molecules and Their Mechanisms;Annual Review of Biochemistry;2024-08-02

2. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

3. Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node;Molecular Oncology;2024-02-16

4. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

5. Combination of bulk RNA sequencing and scRNA sequencing uncover the molecular characteristics of MAPK signaling in kidney renal clear cell carcinoma;Aging;2024-01-12